pretickt

Is NTRA a good stock to buy?

Natera, Inc. · end-of-day data as of Nov 13, 2026

Natera
NTRA · $46.27B
$319.09-1.2%
Nov 13, 2026 · close
$350$400SepOctNov9:3016:003 months +2.4%Nov 13 · close
▲ 4
  • PT$393.16 +23.2%
  • ConsensusBuy · 23
  • Trendbullish
  • Sector▲ +15.9%
Neutral
  • Earnings in104d
  • RSI34
  • Support-2.8%
  • Resistance+0.7%
  • Off 52w high-27.1%
  • Volume0.8x
  • Bollingerlower half
  • News0.00
  • FCF yield+0.1%
  • 52w range$181–$437
  • ATR+6.8%
  • Off ATH-27.1%
▼ 4
  • Insiders-$104M
  • MAs1 of 4
  • MA20×50Death 0d ago
  • MACD-9.77

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Natera a good stock to buy?

Natera is strong on 2 of the 5 questions about the business; weak on economics and execution. With a loss over the last 12 months, Natera has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics losing money
  4. Execution misses
  5. Fragility sturdy
  6. Price like its peers
DemandDo people want more of what it sells?growing

NTRA sales growth revenue growth

+41%a year, for the last 3 years

Natera's sales grew 41% a year for 3 years, to $2.31B in fiscal 2025.

NTRA analysts' forecast revenue estimates

+30%the sales they expect next fiscal year, on the last

Analysts expect Natera's sales to grow 30% to $3B in fiscal 2026 (8 analysts).

NTRA competitors

pretickt analysis+37%its sales in 12 months, on a year before

Natera's sales grew 37% in the 12 months to Sep 30, 2026, faster than Idexx Laboratories (+12%), IQVIA (+9%) and Agilent (+9%), slower than Waters (+81%).

NTRA sales by business revenue by segment

100%of its sales from Product

Product brought Natera 100% of its sales in fiscal 2025; Licensing and other 0%.

Advantage moatIs it hard to copy?some edge

NTRA return on capital ROIC

pretickt analysis-26%earned before tax on the money invested in it

Natera earned -26% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Idexx Laboratories 74%, Agilent 17%, IQVIA 11% and Waters 2%.

NTRA margin on each sale gross margin

65%left after making the product

Natera kept 65% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 52%.

EconomicsDoes it make good money?losing money

NTRA margin after costs profit margin

-9%of sales left after running the business

Natera's operating margin was -9% in the 12 months to Sep 30, 2026, against -66% in fiscal 2022.

ExecutionDoes it deliver what it promises?misses

NTRA earnings vs estimates

2 of 6quarters above the analysts' estimate

Natera beat the analysts' profit estimate in 2 of 6 quarters, the latest on Nov 5, 2026; 2 quarters with one-time gains or charges are left out.

NTRA insider selling

-$348Msold, net, by its executives in 12 months

Natera's executives and directors sold a net $348M of shares in the 12 months to Nov 13, 2026; none bought.

NTRA number of employees

+39%more people in a year

Natera had 6,135 employees at the end of fiscal 2025, 39% more than a year before.

NTRA CEO pay

$14.96Mfor fiscal 2025, 87% of it in stock and options

Natera paid its CEO $14.96M for fiscal 2025, 87% of it in stock and options.

Fragility risksCould something break it?sturdy

NTRA financial health Altman Z-score

31.7Altman Z-score, safe above 3

Natera's Altman Z-score is 31.7 (Nov 13, 2026), above 3, where the safe zone starts.

NTRA quality checks Piotroski score

4 of 9checks passed

Natera passes 4 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on profit, long-term debt, the current ratio, new shares and sales for its assets.

Price valuationIs the price reasonable?like its peers

NTRA price vs profit P/E ratio

—it lost money in 12 months: no P/E

Natera has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

NTRA price vs assets price to book

24.7×times what its assets are worth on paper

Natera trades at 24.7 times its book value (Nov 13, 2026); its competitors' median is 6.6.

NTRA analysts' target price target

+23%to their average target

Analysts' average price target for Natera is $393, 23% above the Nov 13, 2026 close of $319.09.

What is Natera's P/E ratio?

Natera has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Natera trades at 24.7 times its book value (Nov 13, 2026); its competitors' median is 6.6.

Who are Natera's biggest competitors?

pretickt compares Natera with Waters, IQVIA, Agilent and Idexx Laboratories. Natera's sales grew 37% in the 12 months to Sep 30, 2026, faster than Idexx Laboratories (+12%), IQVIA (+9%) and Agilent (+9%), slower than Waters (+81%).

Is Natera profitable?

Natera's operating margin was -9% in the 12 months to Sep 30, 2026, against -66% in fiscal 2022.

Who is dumping Natera stock?

Natera's executives and directors sold a net $348M of shares in the 12 months to Nov 13, 2026; none bought.

How does Natera make money?

Product brought Natera 100% of its sales in fiscal 2025; Licensing and other 0%.

How many employees does Natera have?

Natera had 6,135 employees at the end of fiscal 2025, 39% more than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.